Influenza-Associated Hospitalizations,Singapore, 2004–2008 and 2010–2012

Studies of influenza-associated hospitalizations in tropical settings are lacking. To increase understanding of the effect of influenza in Singapore, we estimated the age-specific influenza-associated hospitalizations for pneumonia and influenza during 2004–2008 and 2010–2012. The rate of hospitalization was 28.3/100,000 person-years during 2004–2008 and 29.6/100,000 person-years during 2010–2012. The age-specific influenza-associated hospitalization rates followed a J-shaped pattern: rates in persons >75 years of age and in children <6 months of age were >47 times and >26 times higher, respectively, than those for persons 25–44 years of age. Across all ages during these 2 study periods, ≈12% of the hospitalizations for pneumonia and influenza were attributable to influenza. The rates and proportions of hospitalizations for influenza, particularly among the very young and the elderly, are considerable in Singapore and highlight the importance of vaccination in protecting populations at risk.     

Encephalitis,Ontario, Canada, 2002–2013

Encephalitis, a brain inflammation leading to severe illness and often death, is caused by >100 pathogens. To assess the incidence and trends of encephalitis in Ontario, Canada, we obtained data on 6,463 Ontario encephalitis hospitalizations from the hospital Discharge Abstract Database for April 2002–December 2013 and analyzed these data using multiple negative binomial regression. The estimated crude incidence of all-cause encephalitis in Ontario was ≈4.3 cases/100,000 persons/year. Incidence rates for infants <1 year of age and adults >65 years were 3.9 and 3.0 times that of adults 20–44 years of age, respectively. Incidence peaks during August–September in 2002 and 2012 resulted primarily from encephalitis of unknown cause and viral encephalitis. Encephalitis occurred more frequently in older age groups and less frequently in women in Ontario when compared to England, but despite differences in population, vector-borne diseases, climate, and geography, the epidemiology was overall remarkably similar in the two regions.     

Banna Virus,China, 1987–2007

Banna viruses (BAVs) have been isolated from pigs, cattle, ticks, mosquitoes, and human encephalitis patients. We isolated and analyzed 20 BAVs newly isolated in China; this finding extends the distribution of BAVs from tropical zone to north temperate climates and demonstrate regional variations in BAV phylogeny and mosquito species possibly involved in BAV transmission.     

Lyme Disease,Virginia, USA, 2000–2011

Lyme disease, caused by the bacterium Borrelia burgdorferi and transmitted in the eastern United States by the black-legged tick (Ixodes scapularis), is increasing in incidence and expanding geographically. Recent environmental modeling based on extensive field collections of host-seeking I. scapularis ticks predicted a coastal distribution of ticks in mid-Atlantic states and an elevational limit of 510 m. However, human Lyme disease cases are increasing most dramatically at higher elevations in Virginia, a state where Lyme disease is rapidly emerging. Our goal was to explore the apparent incongruity, during 2000–2011, between human Lyme disease data and predicted and observed I. scapularis distribution. We found significantly higher densities of infected ticks at our highest elevation site than at lower elevation sites. We also found that I. scapularis ticks in Virginia are more closely related to northern than to southern tick populations. Clinicians and epidemiologists should be vigilant in light of the changing spatial distributions of risk.     

Human Babesiosis,Maine, USA, 1995–2011

We observed an increase in the ratio of pathogenic Babesia microti to B. odocoilei in adult Ixodes scapularis ticks in Maine. Risk for babesiosis was associated with adult tick abundance, Borrelia burgdorferi infection prevalence, and Lyme disease incidence. Our findings may help track risk and increase the focus on blood supply screening.     

Shiga Toxin 1–Producing Shigella sonnei Infections,California, United States, 2014–2015

Shiga toxins (Stx) are primarily associated with Shiga toxin–producing Escherichia coli and Shigella dysenteriae serotype 1. Stx production by other shigellae is uncommon, but in 2014, Stx1-producing S. sonnei infections were detected in California. Surveillance was enhanced to test S. sonnei isolates for the presence and expression of stx genes, perform DNA subtyping, describe clinical and epidemiologic characteristics of case-patients, and investigate for sources of infection. During June 2014–April 2015, we identified 56 cases of Stx1-producing S. sonnei, in 2 clusters. All isolates encoded stx₁ and produced active Stx1. Multiple pulsed-field gel electrophoresis patterns were identified. Bloody diarrhea was reported by 71% of case-patients; none had hemolytic uremic syndrome. Some initial cases were epidemiologically linked to travel to Mexico, but subsequent infections were transmitted domestically. Continued surveillance of Stx1-producing S. sonnei in California is necessary to characterize its features and plan for reduction of its spread in the United States.     

Murine Typhus,Reunion, France, 2011–2013

Murine typhus case was initially identified in Reunion, France, in 2012 in a tourist. Our investigation confirmed 8 autochthonous cases that occurred during January 2011–January 2013 in Reunion. Murine typhus should be considered in local patients and in travelers returning from Reunion who have fevers of unknown origin.     

Kyasanur Forest Disease,India, 2011–2012

To determine the cause of the recent upsurge in Kyasanur Forest disease, we investigated the outbreak that occurred during December 2011–March 2012 in India. Male patients >14 years of age were most commonly affected. Although vaccination is the key strategy for preventing disease, vaccine for boosters was unavailable during 2011, which might be a reason for the increased cases.     

Levofloxacin-Resistant Haemophilus influenzae,Taiwan, 2004–2010

Levofloxacin resistance in Haemophilus influenzae has increased significantly in Taiwan, from 2.0% in 2004 to 24.3% in 2010 (p<0.001). Clinical and molecular investigations of 182 levofloxacin-resistant isolates revealed that the increase was mainly the result of the spread of several clones in the elderly population in different regions.     

Sporotrichosis-Associated Hospitalizations,United States, 2000–2013

To determine frequency and risk for sporotrichosis-associated hospitalizations, we analyzed the US 2000–2013 National (Nationwide) Inpatient Sample. An estimated 1,471 hospitalizations occurred (average annual rate 0.35/1 million persons). Hospitalizations were associated with HIV/AIDS, immune-mediated inflammatory diseases, and chronic obstructive pulmonary disease. Although rare, severe sporotrichosis should be considered for at-risk patients.Key words: sporotrichosis, epidemiology, mycoses, fungi, hospitalization, United States, USASporotrichosis is a fungal disease caused by the Sporothrix schenckii species complex (1). In the environment, S. schenckii is commonly associated with decaying plant matter, soil, and sphagnum moss (2). Infection usually occurs through cutaneous inoculation of the organism and typically is a disease of the skin, subcutaneous tissue, and lymph nodes. Less commonly, disseminated forms of disease can occur if infection spreads from primary to secondary body sites, and pulmonary disease can occur if conidia are inhaled (3). Extracutaneous sporotrichosis typically develops in persons with immunosuppression, chronic obstructive pulmonary disease (COPD), diabetes mellitus, or alcoholism (2). Infections are usually sporadic, but outbreaks have been associated with traumatic skin injury sustained during outdoor work or with zoonotic spread from infected animals (4,5). Considered rare in the United States, sporotrichosis is not a reportable disease, and most information about its epidemiology comes from outbreak investigations.To develop nationally representative estimates and to assess underlying conditions associated with sporotrichosis-associated hospitalizations, we analyzed data from the Healthcare Cost and Utilization Project (HCUP). This family of databases, sponsored by the Agency for Healthcare Research and Quality, comprises the largest collection of publicly available all-payer healthcare data in the United States.     

Research Trends in Mother–Child Healthcare, 1966–1995

Objective: To explore trends in mother–child healthcare (MCHC) research over the past 30 years. Methods: Classifications of Medline articles were made at 5-year intervals using Medical Subject Headings (MeSH) as classifiers. Papers were classified in mutually and non-mutually exclusive categories by subject (mother and four age groups of children) and type of research (clinical, basic, epidemiologic, and unclassified) and its various combinations. Results: The number of MCHC papers increased from 34,110 in 1966 to 65,028 in 1995, but the proportion of all Medline articles (18–21%) was relatively stable. There were remarkable long-term temporal stabilities in the proportions of MCHC papers of mothers and the four age groups of children. Most papers dealt with child (46%) and adolescents (45%), and only 11% studied mother and children together. Regression analysis indicated that a linear increase in number of MCHC papers in Medline (1053/year) was represented largely by single-age and combinations of age children, especially adolescence. However, the slope for mother-plus-children papers (113/year) was substantially higher than for mothers alone (64/year). Clinical papers (52%) were the dominant type of MCHC research, but the proportions of basic and epidemiologic papers and their combinations with clinical papers have increased substantially in the past decade. Conclusions: There has been a dominance of clinical and child-related papers in MCHC research, which may be a reflection of restricted outlooks of specialists in the area. This may change soon if the tendency toward increasing numbers of basic and epidemiologic papers holds.     

Raw Milk Consumption among Patients with Non–Outbreak-related Enteric Infections,Minnesota, USA, 2001–2010

Raw milk has frequently been identified as the source of foodborne illness outbreaks; however, the number of illnesses ascertained as part of documented outbreaks likely represents a small proportion of the actual number of illnesses associated with this food product. Analysis of routine surveillance data involving illnesses caused by enteric pathogens that were reportable in Minnesota during 2001–2010 revealed that 3.7% of patients with sporadic, domestically acquired enteric infections had reported raw milk consumption during their exposure period. Children were disproportionately affected, and 76% of those <5 years of age were served raw milk from their own or a relative’s farm. Severe illness was noted, including hemolytic uremic syndrome among 21% of Escherichia coli O157–infected patients reporting raw milk consumption, and 1 death was reported. Raw milk consumers, potential consumers, and policy makers who might consider relaxing regulations regarding raw milk sales should be educated regarding illnesses associated with raw milk consumption.     

Shiga Toxin–Producing Escherichia coli O157, England and Wales, 1983–2012

We evaluated clinical Shiga toxin–producing Escherichia coli O157 infections in England and Wales during 1983–2012 to describe changes in microbiological and surveillance methods. A strain replacement event was captured; phage type (PT) 2 decreased to account for just 3% of cases by 2012, whereas PT8 and PT21/28 strains concurrently emerged, constituting almost two thirds of cases by 2012. Despite interventions to control and reduce transmission, incidence remained constant. However, sources of infection changed over time; outbreaks caused by contaminated meat and milk declined, suggesting that interventions aimed at reducing meat cross-contamination were effective. Petting farm and school and nursery outbreaks increased, suggesting the emergence of other modes of transmission and potentially contributing to the sustained incidence over time. Studies assessing interventions and consideration of policies and guidance should be undertaken to reduce Shiga toxin–producing E. coli O157 infections in England and Wales in line with the latest epidemiologic findings.     

Hepatitis B vaccination among adolescents 13–17 years,United States, 2006–2012

BackgroundHepatitis B (HepB) vaccination is the most effective measure to prevent HBV infection. Routine HepB vaccination was recommended for infants in 1991 and catch-up vaccination has been recommended for adolescents since in 1995. The purpose of this study is to assess HepB vaccination among adolescents 13–17 years.MethodsThe 2006–2012 NIS-Teen were analyzed. Vaccination trends and coverage by birth cohort among adolescents were evaluated. Multivariable logistic regression and predictive marginal models are used to identify factors independently associated with HepB vaccination.ResultsHepB vaccination coverage increased from 81.3% in 2006 to 92.8% in 2012. Coverage varied by birth cohort and 79–83% received vaccination before 2 years of age for those who were born during 1995 and 1999. Among those who had not received vaccination by 11 years of age, for the 1993–1995 birth cohorts, 9–15% were vaccinated during ages 11–12 years, and 27–37% had been vaccinated through age 16 years. Coverage among adolescents 13–17 years in 2012 ranged by state from 84.4% in West Virginia to 98.7% in Florida (median 93.3%). Characteristics independently associated with a higher likelihood of HepB vaccination included living more than 5 times above poverty level, living in Northeastern or Southern region of the United States, and having a mixed facility as their vaccination provider. Those with a hospital listed as their vaccination provider and those who did not have a well-child visit at age 11–12 years were independently associated with a lower likelihood of HepB vaccination.ConclusionsEfforts focused on groups with lower coverage may reduce disparities in coverage and prevent hepatitis B infection. Parents and providers should routinely review adolescent immunizations. Routine reminder/recall, expanded access in health care settings, and standing order programs should be incorporated into routine clinical care of adolescents.